SAN DIEGO — Gilead Sciences has spent years and billions of dollars to build out its oncology business, most notably by acquiring the cancer cell therapy developer Kite Pharma for $12 billion in 2017. But all that investment, which now includes the approved CAR-T treatment called Yescarta, has yet to deliver commercially.

Yescarta sales are growing each quarter (now totaling $175 million year to date), but the product barely makes a dent in Gilead’s overall income statement. By acquiring Kite, Gilead (GILD) became a leader in cell therapy but it has no presence in the larger and more lucrative immuno-oncology market where Merck (MRK), Roche (RHHBY), and Bristol-Myers Squibb (BMY) dominate.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy